RESUMEN
Psoriasis is a chronic inflammatory skin disease that affects both localized and systemic regions of the body. This condition is characterized by the hyperproliferation of keratinocytes, resulting in skin thickening, scaling, and erythema. The severity of psoriasis depends on the extent of skin involvement, the location of the infection, and the symptoms that the person exhibits. While no cure exists, conventional therapies such as topical and systemic drugs are generally used to manage the exacerbation of symptoms. However, chronic use and overdose can lead to other severe adverse effects. Therefore, scientists and researchers are exploring potential nutraceuticals that can be considered as an alternative source of management for psoriasis. Current research aims to use different combinations of natural compounds like cannabidiol, myo-inositol, eicosapentaenoic acid, and krill oil to study the effect of these compounds in the prevention and treatment of psoriasis in the imiquimod (IMQ)-induced psoriatic mice model. The Psoriasis Area Severity Index (PASI) scoring system is used to analyze skin thickness, scales, and erythema. The results indicate that the krill oil combined with the cannabidiol and myo-inositol shows better results than other nutraceutical combinations. In the future, the natural products of krill oil can be combined with cannabidiol and myo-inositol to create an improved alternative to existing steroidal and nonsteroidal anti-inflammatory drugs for psoriasis treatment.
Asunto(s)
Cannabidiol , Psoriasis , Humanos , Animales , Ratones , Imiquimod/efectos adversos , Cannabidiol/efectos adversos , Psoriasis/inducido químicamente , Psoriasis/tratamiento farmacológico , Piel , Suplementos Dietéticos , Eritema/inducido químicamente , Inositol , Modelos Animales de Enfermedad , Ratones Endogámicos BALB CRESUMEN
This case series describes the outcome of high-dose vitamin D treatment in 6 inpatients with acute skin injury.
Asunto(s)
Eritema , Vitamina D , Humanos , Eritema/inducido químicamente , Eritema/tratamiento farmacológico , Vitaminas , Rayos UltravioletaRESUMEN
BACKGROUND: Periorbital dark circles (PDC) is one of the most common cosmetic issues in today's society. Only moderate degree of improvement has been achieved by various available treatment options. The present study aimed to compare the clinical efficacy of carboxytherapy and fractional CO2 laser therapy in the management of PDC. METHODS: In this split face study, 30 patients with bilateral PDC aged between 23 and 52 years were recruited who underwent carboxytherapy (n = 30) on PDC of one side of the face and fractional CO2 laser therapy (n = 30) on the PDC of other side. The entire treatment comprised of four sessions of each therapy with an interval of 2 weeks each time. The assessment was based on both subjective methods (patients' satisfaction and physician's judgment) and objective method (based on digital standard photographs). The degree of improvement from the patient's point of view (patient satisfaction) and physician's point of view (physician satisfaction) was assessed in different therapy sessions in comparison with the improvement after first session. RESULTS: The study included 30 patients with mean age of 38.22 ± 8.3 years. The mean disease duration was 45 ± 12.3 months. After the second therapy session, patients' satisfaction was remarkably better in the fractional CO2 laser therapy group than the carboxytherapy group, over the time. According to the physician satisfaction, the improvement rate was higher after the second and sixth weeks in the fractional CO2 laser therapy group than the carboxytherapy group; whereas in other sessions, there were no statistically significant differences. There were no significant side effects observed in either group post-treatment each time. CONCLUSION: Fractional CO2 laser therapy is a better option to treat PDC than carboxytherapy. Also, mild side effects (including erythema, pain, and discomfort) were reported in both groups; with no significant difference between the groups.
Asunto(s)
Terapia por Láser , Láseres de Gas , Terapia por Luz de Baja Intensidad , Humanos , Adulto Joven , Adulto , Persona de Mediana Edad , Dióxido de Carbono , Resultado del Tratamiento , Satisfacción del Paciente , Eritema/inducido químicamente , Terapia por Luz de Baja Intensidad/efectos adversos , Terapia por Luz de Baja Intensidad/métodos , Láseres de Gas/efectos adversosRESUMEN
BACKGROUND: Silymarin is the active component of milk thistle, which has antioxidant properties by scavenging free radicals and potential comedolytic properties. AIMS: This study aimed to assess the efficacy and safety of 0.5% silymarin-loaded antioxidant serum (SAS) used to treat mild-to-moderate acne. PATIENTS AND METHODS: A prospective, open-label pilot study was conducted. We enrolled 22 Korean acne patients who applied the 0.5% SAS on the whole face twice daily while continuing the current anti-acne medications. Grade of acne severity, individual lesion counts, sebum output levels, skin erythema, and melanin pigmentation were assessed. RESULTS: After a 4-week application, the modified Global Acne Grading Score (mGAGS), Global Evaluation Acne (GEA) scale, and the acne lesion counts were significantly decreased. Sebum secretion, skin pigmentation, and erythema were also reduced during the study period, yet only the melanin pigmentation index reached statistical significance. Subgroup analysis revealed that the patients who took the low-dose oral isotretinoin during the study period showed more noticeable improvements in skin sebum output and melanin pigmentation. Additionally, no adverse event was associated with using the 0.5% SAS. CONCLUSION: The 0.5% silymarin-containing antioxidant formulation improved acne's clinical severity and related skin biophysical parameters.
Asunto(s)
Acné Vulgar , Silimarina , Humanos , Antioxidantes/efectos adversos , Proyectos Piloto , Silimarina/efectos adversos , Melaninas , Estudios Prospectivos , Acné Vulgar/tratamiento farmacológico , Eritema/inducido químicamente , Resultado del TratamientoRESUMEN
Acne vulgaris (AV) is a common dermatosis that causes psychological problems. Isotretinoin is the first-line treatment for moderate-to-severe AV, but its onset of effect is delayed. Although light-based therapy is widely used in the treatment of AV, there is a lack of reports on delicate pulsed light (DPL) which has a narrow therapeutic spectrum (500-600 nm). Low-level light therapy (LLLT) has shown an emerging role in anti-inflammatory effects and skin repair. This study investigates the efficacy and safety of low-dose oral isotretinoin combined with LLLT using DPL in patients with moderate-to-severe AV. Thirty-six patients with moderate-to-severe AV were enrolled and received low-dose oral isotretinoin (10-20 mg/day). The two sides of the face were randomly assigned to receive DPL (6-9 J/cm2) or not at an interval of 2 weeks for 4 treatment sessions (weeks 0, 2, 4, 6). Photos, GAGS score, counts of papules, pustules, comedones, TEWL, melanin and erythema index, side effects, efficacy, and satisfactory score were recorded at each visit and at 4 weeks after the final treatment (week 10). Thirty-three patients completed the study. DPL and oral isotretinoin combined therapy exhibited significantly improved GAGS score as well as the number of the lesions from week 2 and maintained until week 10. At the end of the observation, the improvement of GAGS was 70.88% on the DPL and isotretinoin combined side versus 62.12% on the side with isotretinoin monotherapy (p = 0.0009). The improvement for papule number was 61.58% on the DPL combined side versus 43.33% on the control side (p < 0.0001), for comedone was 63.15% versus 43.30% (p = 0.0008). TEWL and indexes of melanin and erythema also had better outcomes with DPL combined therapy at week 10. All the side effects were temporary and tolerable; no adverse effects were observed. Oral low-dose isotretinoin combined with LLLT by DPL offers a combination with reduced side effects and better outcomes within a limited treatment duration, which advances the onset of effect of isotretinoin monotherapy and improves lesion clearance.
Asunto(s)
Acné Vulgar , Terapia por Luz de Baja Intensidad , Acné Vulgar/tratamiento farmacológico , Administración Oral , Antiinflamatorios/uso terapéutico , Eritema/inducido químicamente , Eritema/tratamiento farmacológico , Humanos , Isotretinoína/efectos adversos , Melaninas , Resultado del TratamientoRESUMEN
Objective: The expression of therapeutic proteins in plant oil body bioreactors has attracted much attention. But its safety is not yet clear. This article determines the risk of safety after using the drug. Methods: The oil body-linked oleosin-hEGF microgel emulsion (OBEME) was prepared by mixing the xanthan gum with suitable concentrations in an appropriate proportion. Skin irritation and sensitization reaction were investigated in rats and guinea pigs using OBEME as test article.Results: The OBEME did not produce dermal erythema/eschar or oedema responses. The dermal subacute and subchronic toxicity of OBEME were evaluated in accordance with OECD guidelines. Compared with the control group, the basic physical signs, such as weight, feed, drinking, excretion, and behaviour of experimental animals, were not abnormal. In addition, no abnormality was found in haematological parameters, biochemical indexes, relative organ weight, and histopathological observation of organs, and there was no significant difference compared with normal saline treatment group. Therefore, we conclude that OBEME has no toxic effects and is safe and reliable to be used for topical application.
Asunto(s)
Portadores de Fármacos/toxicidad , Factor de Crecimiento Epidérmico/toxicidad , Proteínas de Plantas/toxicidad , Proteínas Recombinantes de Fusión/toxicidad , Piel/efectos de los fármacos , Administración Cutánea , Animales , Reactores Biológicos/efectos adversos , Carthamus tinctorius/genética , Dermatitis por Contacto/diagnóstico , Dermatitis por Contacto/etiología , Dermatitis por Contacto/patología , Portadores de Fármacos/química , Evaluación Preclínica de Medicamentos , Emulsiones , Factor de Crecimiento Epidérmico/administración & dosificación , Factor de Crecimiento Epidérmico/genética , Eritema/inducido químicamente , Eritema/diagnóstico , Cobayas , Humanos , Gotas Lipídicas/química , Masculino , Microgeles , Proteínas de Plantas/administración & dosificación , Proteínas de Plantas/genética , Plantas Modificadas Genéticamente , Ratas , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/genética , Piel/inmunología , Piel/lesiones , Piel/patología , Pruebas de Toxicidad Aguda/métodos , Pruebas de Toxicidad Subaguda/métodos , Pruebas de Toxicidad Subcrónica/métodos , Cicatrización de Heridas/efectos de los fármacosRESUMEN
Morbihan disease is characterized by erythema and solid edema in the two upper thirds of the face. Underlying factors are an imbalance in lymphatic drainage, chronic inflammation, and mast cells leading to fibrosis. Treatment options known thus far have led to unsatisfactory results and have often been associated with a greater risk of side effects; even invasive options have been applied. This study presents four patients treated with a combination of ultra-low-dose isotretinoin and antihistamines for a mean duration of 14 months. While no side effects other than dryness of the lips were noted, a significant reduction of the erythema and edema could be observed in all patients. Specialists evaluated the treatment's success by photodocumentation and measured a 91.5% alleviation of erythema, and 85% reduction of edema, respectively. Based on these results, this new regimen in the therapeutic approach toward Morbihan disease is suggested due to its anti-inflammatory features and low risk of side effects.
Asunto(s)
Acné Vulgar , Isotretinoína , Antiinflamatorios/uso terapéutico , Edema/inducido químicamente , Edema/tratamiento farmacológico , Eritema/inducido químicamente , Eritema/tratamiento farmacológico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Isotretinoína/efectos adversosRESUMEN
BACKGROUND AND OBJECTIVES: The objectives of this study were to evaluate the safety, tolerability, and efficacy of oxymetazoline hydrochloride cream, 1% (oxymetazoline) when used as an adjunctive treatment with energy-based therapy for patients with moderate to severe facial erythema associated with rosacea. STUDY DESIGN/MATERIALS AND METHODS: In this Phase 4, multicenter, interventional, open-label study, eligible patients received one of four energy-based therapies (potassium titanyl phosphate laser, intense pulsed light therapy, pulsed-dye laser Vbeam Perfecta, or pulsed-dye laser Cynergy) on day 1 and day 29 and once-daily application of oxymetazoline on days 3 through 27 and days 31 through 56. Improvement from baseline in Clinician Erythema Assessment (CEA) score, patient satisfaction measures, incidence of treatment-emergent adverse events (TEAEs), and worsening from baseline on dermal tolerability assessments and the Clinician Telangiectasia Assessment (CTA) were assessed. Data were summarized using descriptive statistics. RESULTS: A total of 46 patients (mean age, 51.1 years; 78.3% female) enrolled in this study. Similar numbers of patients received each of the energy-based therapies in addition to oxymetazoline. All patients demonstrated an improvement from baseline in CEA during the study with 39 of 43 evaluable patients (90.7%) demonstrating an improvement 6 hours posttreatment on day 56. Most patients were satisfied or very satisfied with treatment at the end of the study. All TEAEs were mild or moderate in severity. Some patients experienced worsening in dermal tolerability assessment symptoms (range: 4-21 patients; 8.7-45.7%). Worsening in CEA and CTA were each reported by three patients (6.5%) at any time during the study. CONCLUSIONS: Treatment with oxymetazoline as adjunctive therapy with energy-based therapy was safe, well tolerated, and reduced facial erythema in patients with moderate to severe persistent facial erythema associated with rosacea. Lasers Surg. Med. © 2020 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Asunto(s)
Oximetazolina , Rosácea , Eritema/inducido químicamente , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oximetazolina/uso terapéutico , Rosácea/tratamiento farmacológico , Crema para la Piel , Resultado del TratamientoRESUMEN
Benzoyl peroxide (BPO) has been widely used to treat acne vulgaris. Skin flaking, erythema and skin irritation have been observed as side effects of BPO in the treatment of this disorder. In a clinical study, cherry bark-containing jumihaidokuto significantly reduced the erythema induced by BPO application. However, its mechanism of action has not been clarified. In the present study, an application of 10% BPO caused erythema and an increase in interleukin (IL)-1α in the skin of hairless mice, and these changes were significantly suppressed by cherry bark-containing jumihaidokuto at 600 mg/kg. In addition, using a three-dimensional cultured human epidermis model (LabCyte EPI-MODEL), cherry bark-containing jumihaidokuto extract at 250 or 500 µg/mL significantly suppressed IL-1α mRNA expression induced by the application of 0.2 mM BPO. Therefore, cherry bark-containing jumihaidokuto may have suppressed BPO-induced erythema by inhibiting the increase in the IL-1α level in the skin.
Asunto(s)
Peróxido de Benzoílo/efectos adversos , Eritema/inducido químicamente , Eritema/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/uso terapéutico , Acné Vulgar/tratamiento farmacológico , Animales , Peróxido de Benzoílo/uso terapéutico , Células Cultivadas , Quimioterapia Combinada , Epidermis/metabolismo , Eritema/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Interleucina-1alfa/genética , Interleucina-1alfa/metabolismo , Masculino , Ratones Pelados , Corteza de la Planta/química , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , ARN Mensajero/genética , ARN Mensajero/metabolismoAsunto(s)
Kava/efectos adversos , Plantas Medicinales/efectos adversos , Enfermedades de la Piel/patología , Urticaria/patología , Enfermedad Aguda , Cuidados Posteriores , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Biopsia , Diagnóstico Diferencial , Eritema/inducido químicamente , Eritema/patología , Exantema/inducido químicamente , Exantema/patología , Femenino , Humanos , Prednisolona/administración & dosificación , Prednisolona/uso terapéutico , Prurito/inducido químicamente , Prurito/patología , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/inducido químicamente , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/patología , Resultado del Tratamiento , Urticaria/inducido químicamente , Adulto JovenRESUMEN
BACKGROUND: Dual-release mechanism of ethosomal gels (ie, ethosomes and gel) makes them as versatile drug delivery systems for topical applications. Clove oil is obtained from the clove buds exhibited broad antifungal and antibacterial activity. Cutaneous candidiasis is the infection caused by Candida albicans or other Candida species. AIM: The aim of the present study was to prepare ethosomal gel of clove oil and evaluate its effectiveness in the treatment of cutaneous candidiasis. METHODS: Ethosomes of clove oil was formulated by using varying concentrations of soyaphosphotidyl choline and ethanol, and later, it was incorporated into carbapol 974 base gels to form ethosomal gel. The prepared ethosomal gels were also evaluated for spreadability, drug release studies, ex vivo permeation study, and antifungal activity. RESULTS: The optimized formulation did not cause any irritation to the skin since the pH of formulation was in the pH range of skin. The ethosomal gel showed satisfactory antifungal activity against the fungus C. albicans compared to pure clove oil. CONCLUSIONS: The results showed that developed formulation could be promising one in the topical delivery of clove oil for the treatment of cutaneous candidiasis.
Asunto(s)
Candida albicans/efectos de los fármacos , Candidiasis Cutánea/tratamiento farmacológico , Aceite de Clavo/administración & dosificación , Piel/efectos de los fármacos , Administración Cutánea , Animales , Candidiasis Cutánea/microbiología , Aceite de Clavo/efectos adversos , Aceite de Clavo/farmacocinética , Evaluación Preclínica de Medicamentos , Liberación de Fármacos , Eritema/inducido químicamente , Eritema/diagnóstico , Femenino , Geles , Liposomas , Masculino , Pruebas de Sensibilidad Microbiana , Ratas , Índice de Severidad de la Enfermedad , Absorción Cutánea/efectos de los fármacosAsunto(s)
Agastache , Dermatitis Alérgica por Contacto/etiología , Eritema/inducido químicamente , Herpes Zóster/tratamiento farmacológico , Mordeduras y Picaduras de Insectos/tratamiento farmacológico , Fitoterapia/efectos adversos , Preparaciones de Plantas/efectos adversos , Primulaceae , Adolescente , Dermatitis Alérgica por Contacto/patología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Elevated levels of skin sebum are associated with the growth of Propionibacterium acnes. Intensive degreasing of the skin reduces Propionibacterium acnes but also may cause skin irritation. AIMS: We assessed the degreasing effect and skin tolerability of a botanical face cleanser with hops and willow bark extract and disodium cocoyl glutamate as mild cleansing agent compared to a standard face cleanser with sodium laureth sulfate (SLES). MATERIALS AND METHODS: A total of 21 healthy volunteers with normal to oily skin were enrolled in this study. Both cleansers were applied twice a day on the left or right side of the forehead for 15 days in a standardized manner. Bioengineering measurements were performed on day 8 and 15 and on day 17 after an application break of 48 hours. The sebum level was determined using a Sebumeter® , and skin redness was measured using a Mexameter® . RESULTS: The botanical face cleanser significantly reduced the sebum level (P < .01) in the test area on day 17. The SLES containing cleanser showed a statistically relevant degreasing effect already on day 15, but after the application break the sebum level increased again on day 17. None of the cleansers caused skin irritation as determined by skin redness measurements. CONCLUSIONS: In contrast to the SLES containing cleanser, the botanical skin cleanser with hops and willow bark extract had a continuous degreasing effect without reactive seborrhoe after the treatment break. Skin cleansing without SLES might be advantageous for sensitive skin.
Asunto(s)
Eritema/diagnóstico , Extractos Vegetales/administración & dosificación , Sebo/efectos de los fármacos , Crema para la Piel/administración & dosificación , Piel/efectos de los fármacos , Adulto , Eritema/inducido químicamente , Femenino , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Fotometría , Extractos Vegetales/efectos adversos , Extractos Vegetales/química , Sebo/metabolismo , Índice de Severidad de la Enfermedad , Piel/diagnóstico por imagen , Piel/metabolismo , Crema para la Piel/efectos adversos , Crema para la Piel/química , Dodecil Sulfato de Sodio/administración & dosificación , Dodecil Sulfato de Sodio/efectos adversos , Dodecil Sulfato de Sodio/análogos & derivados , Resultado del Tratamiento , Adulto JovenRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Mesoterapia/efectos adversos , Eritema/inducido químicamente , Cosméticos/efectos adversosAsunto(s)
Anticuerpos Monoclonales/efectos adversos , Terapia Biológica/efectos adversos , Erupciones por Medicamentos/etiología , Pénfigo/inducido químicamente , Adulto , Anticuerpos Monoclonales Humanizados , Artritis Reumatoide/tratamiento farmacológico , Erupciones por Medicamentos/patología , Eritema/inducido químicamente , Eritema/patología , Femenino , Humanos , Inmunohistoquímica , Pénfigo/patología , Piel/patologíaAsunto(s)
Humanos , Femenino , Adulto , Terapia Biológica/efectos adversos , Pénfigo/inducido químicamente , Erupciones por Medicamentos/etiología , Anticuerpos Monoclonales/efectos adversos , Artritis Reumatoide/tratamiento farmacológico , Piel/patología , Inmunohistoquímica , Pénfigo/patología , Erupciones por Medicamentos/patología , Eritema/inducido químicamente , Eritema/patología , Anticuerpos Monoclonales HumanizadosRESUMEN
Pemetrexed is a multi-targeted folate antagonists approved for non-small cell lung cancer and other malignancies. Adverse cutaneous reactions have been reported in up to 1/3 of patients treated. A rare cutaneous adverse reaction is pseudocellulitis. We report about a 62-year-old male patient treated with a combination of cisplatin and pemetrexed for non-small cell lung cancer stage IV who developed about 4 months after initiation of treatment painful, non-febrile erythematous lesions on feet and lower legs. There was no lymphadenopathy and no general malaise. Laboratory investigations detected increased level of C-reactive protein but normal values of procalcitonin. A skin biopsy revealed a mild interface dermatitis. Antifolate treatment was stopped and he received oral and topical corticosteroids, compression therapy and supplementation with folate and vitamin B. A complete remission of skin eruptions was achieved. Pemetrexed-induced pseudocellulitis is a possible, but rare complication of treatment that oncologists and dermatologists should know. Systemic antibiosis is unnecessary.
Asunto(s)
Antineoplásicos/efectos adversos , Celulitis (Flemón)/diagnóstico , Edema/diagnóstico , Eritema/diagnóstico , Pemetrexed/efectos adversos , Diagnóstico Diferencial , Edema/inducido químicamente , Eritema/inducido químicamente , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Bleomycin induced flagellate dermatitis is an uncommon and unique adverse effect. With the declining use of bleomycin, this complication is becoming increasingly infrequent in day-to-day clinical practice. We herein describe a case of a 13year old male patient with left thalamic mixed germ cell tumour treated by multimodality approach, who developed flagellate erythema after two cycles of combination chemotherapy with bleomycin, etoposide and cisplatin (BEP). This brief report highlights the importance of awareness and timely identification and management of this dermatological toxicity in patients undergoing bleomycin based combination chemotherapy.